09Jun 2025
Nikkomycin Z Shows Promise in Treating Coccidioidomycosis Safely

Nikkomycin Z Shows Promise in Treating Coccidioidomycosis Safely

Nikkomycin Z demonstrated favorable safety and pharmacokinetics in healthy adults. Administered in oral doses (250–750 mg), it showed dose-dependent plasma concentrations, with peak levels of 3.70–6.89 mg/L at 2.3–3.0 hours. AUC values increased with dose, though bioavailability plateaued at higher levels. The drug was well tolerated over 14 days without serious side effects, supporting its continued development for treating coccidioidomycosis.

  • #oncology

Like

Save

Share